Every 8-K that Fulgent Genetics, Inc. (FLGT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FLGT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FLGT filings page.
Fulgent Genetics reported second quarter 2026 results with revenue of $85.4 million, up from $81.8 million a year earlier, and a GAAP net loss of $29.5 million, or $(1.05) per share. GAAP gross margin was 30.1%, non-GAAP gross margin 31.3%, and non-GAAP net loss $16.2 million.
The company repurchased approximately 1.5 million shares for $23.8 million in the quarter and ended with $551.5 million in cash, cash equivalents, restricted cash and marketable securities, excluding an anticipated $106.1 million tax refund. For 2026, management guides revenue to $330–$340 million, non-GAAP loss of $63–$67 million, non-GAAP loss per share of $2.22–$2.35 and year-end cash of about $610 million. Management linked the guidance revision to processing delays during the final phase of its billing and revenue cycle transition that affected collection rates.
In its therapeutics segment, Fulgent highlighted Phase 2 data for FID‑007 in recurrent/metastatic head and neck cancer, with an objective response rate of 61.9%, one-year overall survival of 63.4%, a manageable safety profile, and plans to advance to a Phase 3 study.
Fulgent Genetics filed an 8-K to share updated clinical data for its cancer drug candidate FID-007. The company presented preliminary Phase 2 results at the ASCO 2026 Annual Meeting in a rapid oral abstract session focused on head and neck cancer.
The open-label, randomized Phase 2 study evaluates two dosing regimens of FID-007 combined with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after PD-1–based immunotherapy. As of the April 16, 2026 data cutoff, investigators reported meaningful clinical activity and a manageable safety profile.
According to a principal investigator, the combination produced an objective response rate of 61.9%, median progression-free survival of 6.7 months, median duration of response of 7.4 months, and one-year overall survival of 63.4%. A Phase 3 study of FID-007 is planned, and the ASCO presentation slides are being made available on Fulgent’s investor relations website.
Fulgent Genetics reported interim Phase 2 results for its cancer drug candidate FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma. The data come from an open-label, randomized study presented in a full abstract at ASCO 2026.
Among 42 efficacy-evaluable patients, the combination showed an objective response rate of 60%, with median progression-free survival of 7.2 months across two dosing arms. Median duration of response was 7.4 months, and over half of responders were still responding at the data cut-off of December 20, 2025.
The safety profile was described as favorable overall, with most treatment-related side effects in grades 1–2, though grade 3–4 events such as neutropenia, anemia, leukopenia and rash occurred, and there was one grade 5 treatment-related pneumonia. Overall survival data remain immature. The abstract is available on ASCO’s site, with final presentation slides to follow on June 1, 2026.
Fulgent Genetics, Inc. reported results from its 2026 annual stockholder meeting. Stockholders approved the Fulgent Genetics, Inc. 2026 Equity Incentive Plan, which authorizes issuance of 2,000,000 new shares of common stock, plus up to 1,500,000 additional shares if awards under the prior plan are forfeited or cancelled on or after the effective date.
The 2026 Plan replaces the Amended and Restated 2016 Omnibus Incentive Plan, although existing awards under the prior plan remain in effect under their current terms. Stockholders also elected four directors to serve until the 2027 annual meeting, ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers.
At the meeting, a quorum of 24,578,996 shares, or approximately 83% of the 29,747,420 shares outstanding and eligible to vote as of March 20, 2026, was present in person or by proxy, indicating strong stockholder participation.
Fulgent Genetics reported first quarter 2026 revenue of $71.1 million, down modestly from $73.5 million a year earlier, with a GAAP net loss of $24.8 million, or $(0.80) per share. Non-GAAP net loss was $11.0 million, or $(0.36) per share, and adjusted EBITDA loss was $15.2 million.
The company ended the quarter with $604.7 million in cash, cash equivalents, restricted cash and marketable securities and used $40.1 million to repurchase about 2.6 million shares. For full-year 2026, Fulgent expects revenue of roughly $350 million, a non-GAAP loss of about $46 million (≈$(1.59) per share), and year-end cash and investments of about $636 million, assuming receipt of approximately $106 million in tax refunds.
Fulgent Genetics completed two related transactions to expand its pathology footprint. Its Inform Diagnostics subsidiary closed a Purchase and Sale Agreement to acquire all equity of dermatopathology lab StrataDx for approximately $13.5 million in cash, subject to post-closing adjustments. It also closed an Asset Purchase Agreement to buy substantially all assets and certain liabilities of Bako Diagnostics for approximately $43.4 million in cash. A joint press release cites a combined purchase price of about $56.9 million for the Bako and StrataDx acquisitions. In connection with the asset deal, Fulgent assumed a lease for roughly 29,099 square feet of lab and office space in Alpharetta, Georgia, running through July 31, 2032, with base rent of $15.54 per square foot from August 1, 2025 and 2% annual increases, plus operating expenses. Required acquired-business financial statements and pro forma financial information will be provided by amendment.
Fulgent Genetics reported fourth-quarter 2025 revenue of $83.3 million, up 9% year over year, and a GAAP net loss of $23.4 million or ($0.76) per share. Non-GAAP income for the quarter was $5.2 million, or $0.16 per diluted share.
For full year 2025, revenue reached $322.7 million, growing 14% year over year. The company posted a GAAP net loss of $60.5 million, or ($1.97) per share, but generated full-year non-GAAP income of $13.2 million, or $0.42 per diluted share.
Fulgent ended 2025 with $705.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of about $106.3 million. For 2026, it guides to revenue of roughly $350 million, a non-GAAP loss of about ($1.45) per share, and year-end cash and investments of about $685 million, assuming receipt of tax refunds and closing of the Bako and StrataDx acquisition.
Fulgent Genetics furnished an 8-K announcing that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The company also updated its investor presentation the same day.
The results press release is furnished under Item 2.02, and the updated presentation is furnished under Item 7.01. These materials are available as Exhibits 99.1 and 99.2. The information in Items 2.02 and 7.01 is being furnished and is not deemed filed or incorporated by reference except as expressly stated in future filings.
Fulgent Genetics reported preliminary clinical data from its ongoing phase 2 study of FID-007 in combination with cetuximab for ≤ 2nd line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma. The company furnished a press release with these details as Exhibit 99.1.